title: Involvement of μ-opioid receptors in antinociceptive action of botulinum toxin type A.
abstract: Botulinum toxin A (BTX-A) is approved for treatment of chronic migraine and has been investigated in various other painful conditions. Recent evidence demonstrated retrograde axonal transport and suggested the involvement of CNS in antinociceptive effect of BTX-A. However, the mechanism of BTX-A central antinociceptive action is unknown. In this study we investigated the potential role of opioid receptors in BTX-A's antinociceptive activity. In formalin-induced inflammatory pain we assessed the effect of opioid antagonists on antinociceptive activity of BTX-A. Naltrexone was injected subcutaneously (0.02-2 mg/kg) or intrathecally (0.07 μg/10 μl-350 μg/10 μl), while selective μ-antagonist naloxonazine was administered intraperitoneally (5 mg/kg) prior to nociceptive testing. The influence of naltrexone (2 mg/kg s.c.) on BTX-A antinociceptive activity was examined additionally in an experimental neuropathy induced by partial sciatic nerve transection. To investigate the effects of naltrexone and BTX-A on neuronal activation in spinal cord, c-Fos expression was immunohistochemically examined in a model of formalin-induced pain. Antinociceptive effects of BTX-A in formalin and sciatic nerve transection-induced pain were prevented by non-selective opioid antagonist naltrexone. Similarly, BTX-A-induced pain reduction was abolished by low dose of intrathecal naltrexone and by selective μ-antagonist naloxonazine. BTX-A-induced decrease in dorsal horn c-Fos expression was prevented by naltrexone. Prevention of BTX-A effects on pain and c-Fos expression by opioid antagonists suggest that the central antinociceptive action of BTX-A might be associated with the activity of endogenous opioid system (involving μ-opioid receptor). These results provide first insights into the mechanism of BTX-A's central antinociceptive activity.
authors.affiliation: Department of Pharmacology, University of Zagreb, Faculty of Pharmacy and Biochemistry, Domagojeva 2, 10000 Zagreb, Croatia. vdrinovac@pharma.hr
authors.forename: V
authors.initials: V
authors.lastname: Drinovac
authors.forename: L
authors.initials: L
authors.lastname: Bach-Rojecky
authors.forename: I
authors.initials: I
authors.lastname: Matak
authors.forename: Z
authors.initials: Z
authors.lastname: Lacković
mesh_terms: D000700:Analgesics / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D000818:Animals; D019274:Botulinum Toxins, Type A / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D008297:Male; D009270:Naloxone / Q000031:analogs & derivatives / Q000494:pharmacology; D009271:Naltrexone / Q000494:pharmacology; D009292:Narcotic Antagonists / Q000494:pharmacology; D020671:Posterior Horn Cells / Q000187:drug effects / Q000378:metabolism; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism; D051381:Rats; D017450:Receptors, Opioid, mu / Q000819:agonists* / Q000037:antagonists & inhibitors*
chemical_list: D000700:Analgesics; D009292:Narcotic Antagonists; D016760:Proto-Oncogene Proteins c-fos; D017450:Receptors, Opioid, mu; D009270:Naloxone; D009271:Naltrexone; C034643:naloxonazine; D019274:Botulinum Toxins, Type A